Literature DB >> 17572841

Pathophysiological significance of adiponectin.

Makoto Nishida1, Tohru Funahashi, Iichiro Shimomura.   

Abstract

Adipose tissue, which classically has been considered as an energy-storing organ, is now viewed as a massive source of bioactive substances such as leptin, tumor necrosis factor (TNF)-alpha, and adiponectin. Adiponectin was discovered to be the most abundant adipose-specific transcript. Its function had been unclear, but epidemiological and clinical studies have demonstrated that serum levels of adiponectin are inversely associated with body weight, especially abdominal visceral fat accumulation. In addition, adiponectin was inversely related to cardiovascular risk factors, such as insulin resistance, blood pressure, and low-density lipoprotein (LDL) cholesterol and triglyceride levels, and was positively related to high-density lipoprotein (HDL) cholesterol levels. Moreover, low adiponectin concentration is associated with a high incidence of cardiovascular disease (CVD), diabetes, some kinds of cancer, and other various diseases. These associations suggest the clinical significance of adiponectin, and a number of investigations are now being conducted to clarify the biological functions of adiponectin. Recent studies have revealed that adiponectin exhibits antiinflammatory, antiatherogenic, and antidiabetic properties. In addition, adiponectin has been thought to be a key molecule in "metabolic syndrome," which is an epidemiological target for preventing cardiovascular disease. Various functions of adiponectin may possibly serve to prevent and treat obesity-related diseases and CVD. Furthermore, enhancement of adiponectin secretion or action may become a promising therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17572841     DOI: 10.1007/s00795-007-0366-7

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.070


  136 in total

Review 1.  Regulators and effectors of the ARF GTPases.

Authors:  J G Donaldson; C L Jackson
Journal:  Curr Opin Cell Biol       Date:  2000-08       Impact factor: 8.382

2.  Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms.

Authors:  Rei Shibata; Kaori Sato; David R Pimentel; Yukihiro Takemura; Shinji Kihara; Koji Ohashi; Tohru Funahashi; Noriyuki Ouchi; Kenneth Walsh
Journal:  Nat Med       Date:  2005-09-11       Impact factor: 53.440

3.  Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the hoorn study.

Authors:  Marieke B Snijder; Robert J Heine; Jacob C Seidell; Lex M Bouter; Coen D A Stehouwer; Giel Nijpels; Tohru Funahashi; Yuji Matsuzawa; Iichiro Shimomura; Jacqueline M Dekker
Journal:  Diabetes Care       Date:  2006-11       Impact factor: 19.112

4.  Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.

Authors:  Aki Hiuge; Alexander Tenenbaum; Norikazu Maeda; Michal Benderly; Masahiro Kumada; Enrique Z Fisman; David Tanne; Zipora Matas; Toshiyuki Hibuse; Koichi Fujita; Hitoshi Nishizawa; Yehuda Adler; Michael Motro; Shinji Kihara; Iichiro Shimomura; Solomon Behar; Tohru Funahashi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-12-28       Impact factor: 8.311

5.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

6.  Plasma adiponectin and gastric cancer.

Authors:  Makoto Ishikawa; Joji Kitayama; Shinsuke Kazama; Takeyuki Hiramatsu; Kenji Hatano; Hirokazu Nagawa
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

7.  Plasma adiponectin levels and risk of myocardial infarction in men.

Authors:  Tobias Pischon; Cynthia J Girman; Gokhan S Hotamisligil; Nader Rifai; Frank B Hu; Eric B Rimm
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

8.  Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL.

Authors:  Hiroyuki Motoshima; Xiangdong Wu; Kalyankar Mahadev; Barry J Goldstein
Journal:  Biochem Biophys Res Commun       Date:  2004-03-05       Impact factor: 3.575

9.  Decreased plasma adiponectin concentrations in women with dyslipidemia.

Authors:  Miyao Matsubara; Shoji Maruoka; Shinji Katayose
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

10.  Hypoadiponectinemia is an independent risk factor for hypertension.

Authors:  Yoshio Iwashima; Tomohiro Katsuya; Kazuhiko Ishikawa; Noriyuki Ouchi; Mitsuru Ohishi; Ken Sugimoto; Yuxiao Fu; Masaharu Motone; Kouichi Yamamoto; Akiko Matsuo; Koji Ohashi; Shinji Kihara; Tohru Funahashi; Hiromi Rakugi; Yuji Matsuzawa; Toshio Ogihara
Journal:  Hypertension       Date:  2004-05-03       Impact factor: 10.190

View more
  45 in total

1.  Up-regulation of rat adipose tissue adiponectin gene expression by long-term but not by short-term food restriction.

Authors:  Jacek Turyn; Justyna Korczynska; Malgorzata Presler; Ewa Stelmanska; Elzbieta Goyke; Julian Swierczynski
Journal:  Mol Cell Biochem       Date:  2008-03-08       Impact factor: 3.396

2.  Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome.

Authors:  Edmond P Wickham; Kai I Cheang; John N Clore; Jean-Patrice Baillargeon; John E Nestler
Journal:  Metabolism       Date:  2010-03-31       Impact factor: 8.694

3.  The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease.

Authors:  Yuichiro Eguchi; Toshihiko Mizuta; Yoshio Sumida; Eriko Ishibashi; Yoichiro Kitajima; Hiroshi Isoda; Hiroko Horie; Takaya Tashiro; Eri Iwamoto; Hirokazu Takahashi; Takuya Kuwashiro; Shu Soejima; Yasunori Kawaguchi; Yasutomo Oda; Sei Emura; Ryuichi Iwakiri; Iwata Ozaki; Takahisa Eguchi; Naofumi Ono; Keizo Anzai; Kazuma Fujimoto; Shunzo Koizumi
Journal:  J Gastroenterol       Date:  2010-11-02       Impact factor: 7.527

4.  Brief Report: Association of Adipokines With Bone Mineral Density in HIV-Infected and HIV-Uninfected Women.

Authors:  Anjali Sharma; Yifei Ma; Rebecca Scherzer; Amber L Wheeler; Mardge Cohen; Deborah R Gustafson; Sheila M Keating; Michael T Yin; Phyllis C Tien
Journal:  J Acquir Immune Defic Syndr       Date:  2016-12-01       Impact factor: 3.731

5.  Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study.

Authors:  Stacy A Porter; Alison Pedley; Joseph M Massaro; Ramachandran S Vasan; Udo Hoffmann; Caroline S Fox
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-15       Impact factor: 8.311

Review 6.  Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease.

Authors:  Tamotsu Takeuchi; Yoshihiro Adachi; Yuji Ohtsuki; Mutsuo Furihata
Journal:  Med Mol Morphol       Date:  2007-09-18       Impact factor: 2.309

7.  Circulating adiponectin represents a biomarker of the association between adiposity and bone mineral density.

Authors:  Kemal Ağbaht; Alper Gürlek; Jale Karakaya; Miyase Bayraktar
Journal:  Endocrine       Date:  2009-03-14       Impact factor: 3.633

8.  Adiponectin receptor expression in gastric carcinoma: implications in tumor development and progression.

Authors:  Eun Shin; Do Joong Park; Hyung-Ho Kim; Nam Hee Won; Gheeyoung Choe; Hye Seung Lee
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-29       Impact factor: 4.553

9.  Hypoadiponectinemia, cardiometabolic comorbidities and left ventricular hypertrophy.

Authors:  Tiziana Di Chiara; Christiano Argano; Alessandra Scaglione; Giovanni Duro; Salvatore Corrao; Rosario Scaglione; Giuseppe Licata
Journal:  Intern Emerg Med       Date:  2014-07-18       Impact factor: 3.397

10.  Gender differences relating to metabolic syndrome and proinflammation in Finnish subjects with elevated blood pressure.

Authors:  Tiina Ahonen; Juha Saltevo; Markku Laakso; Hannu Kautiainen; Esko Kumpusalo; Mauno Vanhala
Journal:  Mediators Inflamm       Date:  2009-08-20       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.